Pursuing Solutions in  Immunology Targeting Diabetes JOHNSON & JOHNSON 2010 ANNUAL REPORT 9 Elizabeth Menduke,  47 , lives  outside Los Angeles, where  she owns her own business.  As a result of her psoriasis,  she once had scaly red  patches on more than 70  percent of her body. After  treatment with  STELARA ® (ustekinumab) for plaque  psoriasis, Elizabeth says, “I am so very excited to have  clearer skin again.” STELARA ® , a treatment  approved for moderate to  severe plaque psoriasis, is  now available in more than  50  countries as a result of  additional marketing  approvals in  2010 .  Another treatment,  SIMPONI ®  (golimumab),  approved in  2009  for the treat- ment of rheumatoid arthritis,  psoriatic arthritis and ankylosing spondylitis, is now  approved in approximately 40  countries. Two additional applications filed in  2010  seek to expand the U.S. label to  include inhibition of the  progression of structural  damage in the treatment of  rheumatoid arthritis and psoriatic arthritis. REMICADE ®  (infliximab), a treatment with  15  FDA  approvals, also received addi- tional marketing approvals in  2010 , including several in Japan.  In all,  REMICADE ®  is available in  100  countries.  Such incremental growth  with existing products is an  important strategy for the  Immunology Therapeutic Area,  which also expanded research  and development capabilities  into new treatment areas.  In June, Centocor Ortho  Biotech Inc. acquired RespiVert  Ltd., a drug discovery company  focused on developing inhaled  small-molecule therapies for  the treatment of pulmonary  diseases. Sue Dillon, Ph.D., Global  Therapeutic Area Head,  Immunology, explains that the acquisition strengthens  capabilities to further build a  pipeline of novel oral and  biologic therapies. “We’re focused on areas such  as asthma, chronic obstructive  pulmonary disease, idiopathic  pulmonary fibrosis, sarcoidosis  and lupus,” says Dillon, “where  we can continue to make a  difference in patients’ lives.” CLEARER SKIN  Psoriasis once  kept Elizabeth Menduke from  feeling her best. But she has  clearer skin after treatment with  STELARA ®  for plaque psoriasis. Worldwide,  300  million  people live with diabetes— almost equal to the entire U.S. population.  “Diabetes is a far-reaching,  complex disease,” says Martin  Fitchet, M.D., Head of the  Cardiovascular and  Metabolism Therapeutic Area.  “We are working to develop  new treatment options that  will not only help better  manage the disease but have  the potential to limit its  progression.”  In  2010 , a large clinical  development program for  canagliflozin* and new collaborations supported the  Company’s commitment to  build a portfolio of diabetes  treatments.  Canagliflozin is an investigational oral, selective  sodium-glucose transporter- 2 (SGLT 2 ) inhibitor being  studied in patients for the  treatment of type  2  diabetes.  The Phase III clinical trial  program involves more than  10,000  patients.  A new collaboration with  Metabolex, Inc. focuses on discovering, developing and  commercializing new treatment options for people  with type  2  diabetes and  obesity. An agreement was  entered into with Diamyd  Medical AB to support the  development of pharmaceuti- cals targeting autoimmune  diabetes and its complica- tions, in particular the  treatment and prevention of type  1  diabetes.  *Canagliflozin is developed in  collaboration with Mitsubishi- Tanabe Pharma Corporation.